developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagsgene editing

#gene editing

All articles tagged with "gene editing"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Archive
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

gene editing Articles | Developments Today

Clinician-led approach could give doctors a control dial for cell therapies

Prime Editing May Give Cell Therapies a Drug-Controlled Dial

WEHI-led researchers reported a prime-editing platform in Blood.
The approach is designed to make therapeutic T cells resistant to a commonly used immunosuppressive drug.
The work is preclinical research and not an established patient treatment.

DE

DT Editorial Team·Oct 20, 2026·via medicalxpress.com

More in Health→

Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE | European Journal of Human Genetics (via www.nature.com)

Embryo Editing and Embryo Selection Need Joint Governance, Nature Medicine Argues

A Nature Medicine commentary published 23 September 2026 argues embryo editing and embryo selection require joint governance.
The two practices are increasingly used together in the same clinical decision but are overseen by separate regulatory traditions.
Embryo selection is governed largely through clinical practice and consent rules; editing through research safety and ethics frameworks.
The commentary calls for shared definitions, coordinated oversight bodies, common evidence standards, transparency and international alignment.

DE

DT Editorial Team·Sep 25, 2026·via nature.com

More in Health→

Chinese university investigating girl's death in gene-editing trial

Chinese University Opens Probe Into Undisclosed Death in Brain Gene-Editing Trial

Shanghai Jiao Tong University says it opened a special working group to investigate the case.
A six-year-old girl reportedly died about a week after receiving an experimental brain-directed gene-editing treatment.
The supplied report says the death was not disclosed in later related scientific work by the lead researcher.
The case raises questions about informed consent, oversight, adverse-event reporting, and pay-to-participate experimental care.

DE

DT Editorial Team·Jul 26, 2026·via medicalxpress.com

More in Health→

One-time gene editing treatment lowers 'bad' cholesterol by up to 62%

One-Shot Gene Editing Therapy Cuts LDL Cholesterol in Early Trial

A Phase 1b study tested VERVE-102 in 35 adults with inherited high cholesterol or early coronary artery disease.
At the highest dose, LDL cholesterol fell by up to 62% after a single infusion.
The therapy works by switching off the PCSK9 pathway in the liver, aiming for a durable one-time effect.

DE

DT Editorial Team·May 31, 2026·via medicalxpress.com

More in Health→

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

Eli Lilly Says Verve Gene-Editing Therapy Cut Cholesterol in Early Trial

Lilly says a high dose of VERVE-102 reduced cholesterol by 62% in an early study.
The result points to early biological activity for a gene-editing therapy.
Key questions on safety, durability, and larger-trial performance remain open.

DE

DT Editorial Team·May 25, 2026·via statnews.com

More in Health→

CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial - Nature Medicine

CRISPR-Edited Bone Marrow Transplant Strategy Shows Early Promise in High-Risk AML

A phase 1/2a trial tested a CRISPR-edited allogeneic transplant product lacking CD33 in high-risk AML and MDS.
All 30 treated patients achieved neutrophil engraftment by day 28, with a median time of 10 days.
Nineteen patients received gemtuzumab ozogamicin maintenance, which was tolerated up to the recommended phase 2 dose.

DE

DT Editorial Team·May 12, 2026·via nature.com

More in Health→

Intellia

Intellia’s Phase 3 Result Marks a Turning Point for In Vivo CRISPR Medicine

Intellia’s in vivo CRISPR therapy reportedly succeeded in a Phase 3 trial.
The result is described as a first for an in vivo CRISPR treatment.
The milestone could put the therapy on track for potential FDA approval.
The outcome is significant for the broader field of gene editing delivered directly inside the body.

DE

DT Editorial Team·Apr 28, 2026·via endpoints.news

More in Health→

Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next

Phase 3 CRISPR Success Gives Gene Editing a New Clinical Milestone

Intellia says its gene-editing treatment for hereditary angioedema succeeded in Phase 3.
The result is framed as the company’s first Phase 3 CRISPR readout, making it a significant field milestone.
Detailed data are not included in the supplied text, but the late-stage success marks an important validation step for gene editing.

DE

DT Editorial Team·Apr 28, 2026·via endpoints.news

More in Health→

Gene-Edited Immune Cells Turn the Body Into a Protein Factory in Mouse Study

Researchers reported that editing a small number of stem cells enabled long-term antibody production in mice.
The engineered response was boostable and protected mice from deadly influenza infections.
The platform could eventually support therapies beyond infectious disease, including metabolic disorders and cancer.

DE

DT Editorial Team·Apr 16, 2026·via medicalxpress.com

More in Health→

Compact CRISPR system points toward more practical in-body gene editing

Phys.org says researchers identified an enhanced CRISPR system with a compact design.
The source frames targeted in-body delivery as a key step toward broader clinical use.
The report cites efficiencies of up to 90%.

DE

DT Editorial Team·Apr 14, 2026·via phys.org

More in Science→